Discovery of Pyrazolo[1,5- a ]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c01374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Ying-Zhe Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 2100…. Hauptthemen laut MEDLINE: Dioxygenases, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Qinglan Project of Jiangsu Province of China, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
M6A (N6-methyladenosine) plays a significant role in regulating RNA processing, splicing, nucleation, translation, and stability. AlkB homologue 5 (ALKBH5) is an Fe(II)/2-oxoglutarate (2-OG)-dependent dioxygenase that demethylates mono- or dimethylated adenosines. ALKBH5 can be regarded as an oncogenic factor for various human cancers. However, the discovery of potent and selective ALKBH5 inhibitors remains a challenge. We identified DDO-2728 as a novel and selective inhibitor of ALKBH5 by structure-based virtual screening and optimization. DDO-2728 was not a 2-oxoglutarate analogue and could selectively inhibit the demethylase activity of ALKBH5 over FTO. DDO-2728 increased the abundance of m6A modifications in AML cells, reduced the mRNA stability of TACC3, and inhibited cell cycle progression. Furthermore, DDO-2728 significantly suppressed tumor growth in the MV4-11 xenograft mouse model and showed a favorable safety profile. Collectively, our results highlight the development of a selective probe for ALKBH5 that will pave the way for the further study of ALKBH5 targeting therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Zheng-Yu Jiang, Qi-Dong You, Xiao-Ke Guo
Förderung
- Qinglan Project of Jiangsu Province of China
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y. Z., Li, H. Y., Zhang, Y., Jiang, R. X., Xu, J., Gu, J., Jiang, Z., Jiang, Z. Y., You, Q. D., & Guo, X. K. (2023). Discovery of Pyrazolo[1,5- a ]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01374
Vancouver
Wang YZ, Li HY, Zhang Y, Jiang RX, Xu J, Gu J, et al. Discovery of Pyrazolo[1,5- a ]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01374
BibTeX
@article{Wang2023,
author = {Wang, Ying-Zhe and Li, Hong-Yu and Zhang, Yan and Jiang, Rui-Xin and Xu, Jun and Gu, Jing and Jiang, Zheng and Jiang, Zheng-Yu and You, Qi-Dong and Guo, Xiao-Ke},
title = {Discovery of Pyrazolo[1,5- a ]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c01374}
}
EUVIMED